Lumigan just as effective as latanoprost/timolol combination

Article

Treatment with bimatoprost (Lumigan; Allergan) alone is as effective at lowering intraocular pressure (IOP) as a fixed combination of latanoprost and timolol.

Treatment with bimatoprost (Lumigan; Allergan) alone is as effective at lowering intraocular pressure (IOP) as a fixed combination of latanoprost and timolol, according to the results of a study published in the December 2007 issue of Ophthalmology.

Luca Rossetti from the University of Milan, Italy and colleagues from centres in Germany, the United Kingdom, Greece and Switzerland enrolled 200 patients with glaucoma or ocular hypertension into a randomized, double-masked, multicentre clinical trial to compare the effect of bimatoprost and a fixed combination of latanoprost and timolol (LTFC) on 24-hour mean IOP.

Included in the study were patients who were controlled (IOP < 21 mmHg) on the non-fixed combination of latanoprost and timolol for at least three months before the baseline visit or patients on monotherapy with either latanoprost or timolol who were eligible for dual therapy not being fully controlled on monotherapy. The latter group of patients underwent a six-week wash-in phase with the non-fixed combination of latanoprost and timolol before baseline IOP determination and study inclusion. Supine and sitting position IOPs were recorded at 8 pm, midnight, 5 am, 8 am, noon and 4 pm at baseline, six week and 12 week follow-up.

Mean baseline IOPs were 16.3±3.3 mmHg and 15.5±2.9.mmHg in the bimatoprost and LTFC groups, respectively. At week 12, mean IOPs were 16.1±2.5 mmHg for the bimatoprost group and 16.3±3.7 mmHg for the LTFC group. No significant differences between the two treatment groups were found. As compared with baseline, mean IOP increased by 0.3±3.6 mmHg during the day and decreased by 0.8±3.8 mmHg during the night in the bimatoprost group, whereas there were increases of 1.43±2.6 mmHg during the day and 0.14±3.2 mmHg at night in the LTFC group.

The authors of the study concluded that bimatoprost is not inferior to LTFC in maintaining IOP at a controlled level during a 24-hour period in patients who switched from the non-fixed combination of latanoprost and timolol.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.